Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-Deoxy-thymidine-beta-L-rhamnose is a pyrimidine nucleotide sugar, specifically a glycosylated derivative of thymidine that incorporates the sugar rhamnose. It is primarily known as a key intermediate in the biosynthesis of dTDP-L-rhamnose, which is an essential precursor for the formation of bacterial cell wall polysaccharides and lipopolysaccharides[1][3][4]. The compound participates in enzymatic reactions catalyzed by glycosyltransferases and reductases such as RmlC and WsaF, which are involved in rhamnan chain assembly[5][8]. Biologically, it has been studied for its potential antiviral activity—by inhibiting viral glycoprotein synthesis—and anticancer properties through disruption of bacterial cell wall biosynthesis and immune modulation[4]. Its mechanism involves incorporation into polysaccharides/glycoproteins, leading to interference with cell wall synthesis or viral replication. It is considered experimental with no approved clinical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-deoxy-thymidine-beta-L-rhamnose.